BioCentury | Jul 10, 2019
Distillery Therapeutics

Reducing adipogenesis by fibroadipogenic precursors could treat limb-girdle muscular dystrophy

DISEASE CATEGORY: Musculoskeletal INDICATION: Muscular dystrophy Inhibiting ANXA2 or MMP could treat limb-girdle muscular dystrophy (LGMD2B) by preventing fibroadipogenic precursor cells from accumulating and undergoing adipogenesis. In three patients with LGMD2B, which is caused by...
BioCentury | Mar 29, 2019
Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

New and emerging targets at AACR 2019 show cancer researchers are gaining granularity on how to manipulate the tumor microenvironment, a top priority goal for the field. The targets point to emerging strategies for modulating...
BioCentury | Mar 22, 2019
Targets & Mechanisms

Deconvoluting translation at Scripps

With three institutes now under one roof, Scripps Research has established both its own pipeline and a non-profit funding model to bring candidates through early stage clinical trials. Diverging from the philanthropy and investor-based approaches...
BioCentury | Oct 25, 2018
Distillery Therapeutics

Neurology

INDICATION: Cognitive dysfunction Mouse studies suggest inhibiting microglial activation could help treat obesity-associated cognitive dysfunction. In hippocampal tissue from a mouse model of obesity-associated cognitive dysfunction, microglia activation scores were higher than in normal mice....
BioCentury | May 30, 2018
Distillery Therapeutics

Neurology

INDICATION: Stroke Cell culture and mouse studies suggest an ANXA5-targeting, single-chain variable fragment (scFv)-based fusion protein could help treat stroke. The protein consists of an scFv derived from a mouse IgM antibody targeting ANXA5, which...
BioCentury | Jan 11, 2017
Distillery Therapeutics

Cancer

INDICATION: Pancreatic cancer Cell culture and mouse studies suggest dual inhibition of the HGF/SF / c-MET / Src and SHH / IGF-1 / IGF1R pathways could help treat pancreatic ductal adenocarcinoma (PDAC). In human PDAC...
BioCentury | Dec 22, 2016
Targets & Mechanisms

Opportunity Knocks

Despite its continued emphasis on tapping external innovation for new opportunities, industry is still leaving on the table scores of unexploited drug targets identified at universities, according to an analysis of BioCentury’s BCIQ: BioCentury Online...
BioCentury | Dec 17, 2015
Distillery Therapeutics

Therapeutics: Annexin A1 (ANXA1)

Autoimmune disease INDICATION: Rheumatoid arthritis (RA) Patient sample, cell culture and mouse studies suggest neutrophil-derived ANXA1-positive microvesicles could help treat RA. In patients, numbers of neutrophil-derived ANXA1-positive microvesicles were higher in synovial tissues than in...
BioCentury | Sep 17, 2015
Distillery Therapeutics

Therapeutics: Annexin A2 (ANXA2); semaphorin 3D (SEMA3D)

Cancer INDICATION: Pancreatic cancer In vitro and mouse studies suggest inhibiting ANXA2 or SEMA3D could help treat metastatic pancreatic ductal adenocarcinoma (PDAC). In human PDAC samples, high SEMA3D levels were associated with early disease recurrence...
BioCentury | Mar 5, 2015
Distillery Therapeutics

Therapeutics: Annexin A1 (ANXA1)

Cardiovascular disease INDICATION: Atherosclerosis Mouse studies suggest plaque-targeting nanoparticles loaded with an ANXA1 peptide could help prevent cardiac events in atherosclerosis patients. Nanoparticles targeting the collagen type IV component of atherosclerotic plaques were loaded with...
Items per page:
1 - 10 of 28